{"id":"botulinum-toxin-a-50u","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Neck pain"},{"rate":"5-10","effect":"Injection site pain or bruising"},{"rate":"5-15","effect":"Muscle weakness (localized)"},{"rate":"1-5","effect":"Ptosis (eyelid drooping)"},{"rate":"1-5","effect":"Diplopia (double vision)"}]},"_chembl":{"chemblId":"CHEMBL4297862","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Botulinum toxin A is a neurotoxin that irreversibly cleaves SNARE proteins (specifically SNAP-25) required for acetylcholine vesicle fusion and release at the presynaptic terminal. This prevents neuromuscular transmission and results in flaccid paralysis of the targeted muscle. The effect is temporary, lasting 3-4 months, after which nerve terminals regenerate and muscle function returns.","oneSentence":"Botulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:26.682Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cervical dystonia"},{"name":"Blepharospasm"},{"name":"Strabismus"},{"name":"Chronic migraine"},{"name":"Hyperhidrosis"},{"name":"Facial wrinkles and dynamic expression lines (cosmetic)"}]},"trialDetails":[{"nctId":"NCT03848143","phase":"PHASE2","title":"Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain","status":"COMPLETED","sponsor":"Isabel Moreno Hay","startDate":"2019-09-11","conditions":"Neuropathic Pain","enrollment":10},{"nctId":"NCT06839118","phase":"PHASE3","title":"Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache","status":"RECRUITING","sponsor":"Danish Headache Center","startDate":"2025-01-10","conditions":"Posttraumatic Headache","enrollment":80},{"nctId":"NCT06824324","phase":"PHASE1, PHASE2","title":"The Use of Botulinum Toxin in the Management of Myofascial Pain Syndrome","status":"COMPLETED","sponsor":"Yassir R. Al-khannaq","startDate":"2024-03-12","conditions":"Myofacial Pain Syndrome","enrollment":14},{"nctId":"NCT01177358","phase":"PHASE2","title":"Botox in the Healing of Surgical Wounds of the Neck","status":"COMPLETED","sponsor":"Nova Scotia Health Authority","startDate":"2010-05-31","conditions":"Scar","enrollment":40},{"nctId":"NCT05428930","phase":"PHASE1","title":"Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines","status":"COMPLETED","sponsor":"CKD Bio Corporation","startDate":"2022-06-22","conditions":"Glabellar Lines","enrollment":30},{"nctId":"NCT02858219","phase":"PHASE3","title":"A Pilot Study of the Effects of Botulinum Toxin in the Treatment of Provoked Vestibulodynia","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2010-05-04","conditions":"Vestibulodynia","enrollment":60},{"nctId":"NCT05012566","phase":"PHASE2","title":"Onabotulinumtoxin A and Hyaluronic Acid Fillers in the Treatment of Facial Paralysis","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2021-07-14","conditions":"Hemifacial Paralysis","enrollment":70},{"nctId":"NCT03571334","phase":"PHASE2","title":"Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Medical College of Wisconsin","startDate":"2020-07-08","conditions":"Peripheral Neuropathy Due to Chemotherapy","enrollment":40},{"nctId":"NCT03199534","phase":"PHASE4","title":"A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction","status":"COMPLETED","sponsor":"EvergreenHealth","startDate":"2017-05-25","conditions":"Pelvic Pain, Dyspareunia, Pelvic Floor Dysfunction","enrollment":20},{"nctId":"NCT04794504","phase":"PHASE2","title":"Investigating Temporalis and Masseter Botox Injection Before Orthognathic Surgery to Improve Postoperative Pain","status":"NOT_YET_RECRUITING","sponsor":"Kingsway Oral & Maxillofacial Surgery","startDate":"2021-04-19","conditions":"Pain, Postoperative","enrollment":64},{"nctId":"NCT03796351","phase":"PHASE1","title":"Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2012-09","conditions":"Healthy Volunteers","enrollment":25},{"nctId":"NCT03760198","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2018-08-03","conditions":"Hyperhidrosis Primary Focal Axilla","enrollment":220},{"nctId":"NCT03894748","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2011-12","conditions":"Glabella Line Severity","enrollment":168},{"nctId":"NCT03647982","phase":"PHASE1","title":"Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers","status":"COMPLETED","sponsor":"Medy-Tox","startDate":"2018-03-20","conditions":"Anhidrotic Area, Hyperhidrosis","enrollment":13},{"nctId":"NCT02498769","phase":"PHASE1, PHASE2","title":"Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery","status":"COMPLETED","sponsor":"Joseph Mathew, M.D.","startDate":"2015-09","conditions":"Atrial Fibrillation","enrollment":130},{"nctId":"NCT02886988","phase":"PHASE2, PHASE3","title":"Early Postoperative Prevention and Treatment of Median Sternotomy Scars With Botulinum Toxin Type A Injection","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2016-10","conditions":"Scar","enrollment":17},{"nctId":"NCT02460107","phase":"EARLY_PHASE1","title":"Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy","status":"TERMINATED","sponsor":"Catholic University of Korea Saint Paul's Hospital","startDate":"2015-05","conditions":"Neuralgia","enrollment":9},{"nctId":"NCT00575016","phase":"PHASE2","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder","status":"TERMINATED","sponsor":"Allergan","startDate":"2007-12","conditions":"Overactive Bladder","enrollment":74},{"nctId":"NCT02425176","phase":"PHASE2, PHASE3","title":"Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2009-09","conditions":"Sialorrhea","enrollment":30},{"nctId":"NCT01515371","phase":"PHASE2","title":"Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring","status":"TERMINATED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2012-01","conditions":"Habitual Snoring","enrollment":8},{"nctId":"NCT01489904","phase":"PHASE2, PHASE3","title":"Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy","status":"UNKNOWN","sponsor":"Hospital Vall d'Hebron","startDate":"2011-11","conditions":"Sialorrhea, Cerebral Palsy","enrollment":60},{"nctId":"NCT01088230","phase":"PHASE1, PHASE2","title":"The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke","status":"COMPLETED","sponsor":"New York Presbyterian Hospital","startDate":"2009-06","conditions":"Stroke","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BOTOX®","OnabotulinumtoxinA"],"phase":"marketed","status":"active","brandName":"Botulinum toxin A 50u","genericName":"Botulinum toxin A 50u","companyName":"EvergreenHealth","companyId":"evergreenhealth","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Botulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}